Photodynamic therapy for age-related macular degeneration

Age and Ageing

Volumn 31, Issue 1, 2002, Pages 5-6

  Franks, Wendy ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; PLACEBO;

AGED; ARGON LASER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE CLASSIFICATION; DRUG COST; FLUORESCENCE ANGIOGRAPHY; HUMAN; LASER SURGERY; LICENCE; MAJOR CLINICAL STUDY; NOTE; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT INDICATION; VISUAL IMPAIRMENT;

AGE FACTORS; AGED; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 0036184860     PISSN: 00020729     EISSN: None     Source Type: Journal    
DOI: 10.1093/ageing/31.1.5     Document Type: Note

References (5)

1. Causes of Blindness and Partial Sight in England and Wales 1990-1991
2. The Framingham Eye Study Monograph: An ophthalmological study of cataract, glaucoma, diabetic retinopathy and macular degeneration and visual acuity in a general population of 2631 adults 1973-1975
3. Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: Two year results of a randomised clinical trial including lesions with occult with no classic choroidal in Photodynamic Therapy Report 2
4. Age related macular degeneration. New hope for a common problem
5. Photodynamic therapy for neovascular age-related macular degeneration